Latest Fairmount Funds Management LLC Stock Portfolio
$1.51Billion | No. of Holdings #12
Fairmount Funds Management LLC Performance
2026 Q2+23.81%
YTD+46.42%
2025+70.58%
About Fairmount Funds Management LLC and 13F Hedge Fund Stock Holdings
On 2026-08-14, the fund reported it's updated stock portfolio. In the 13F Holdings report, Fairmount Funds Management LLC reported an equity portfolio of $1.5 Billions as of 30 Jun, 2026. <br><br> The top stock holdings of Fairmount Funds Management LLC are , , GLTO. The fund has invested 23.3% of it's portfolio in ORUKA THERAPEUTICS INC and 16.4% of portfolio in DIANTHUS THERAPEUTICS INC. <br><br> The fund managers got completely rid off SPYRE THERAPEUTICS INC (AGLE) stocks. Fairmount Funds Management LLC opened new stock positions in FAETH THERAPEUTICS INC (SNSE). The fund showed a lot of confidence in some stocks as they added substantially to VIRIDIAN THERAPEUTICS INC (VRDN).
Fairmount Funds Management LLC Equity Portfolio Value
Last Reported on: 14 Aug, 2026
$1.51Billion
as of Aug 14, 2026Fairmount Funds Management LLC Annual Return Estimates Vs S&P 500
Our best estimate is that Fairmount Funds Management LLC made a return of 23.81% in the last quarter. In trailing 12 months, it's portfolio return was 179.64%.
- Performance
- S&P 500
New Buys
| Ticker | $ Bought |
|---|---|
| faeth therapeutics inc | 18,050,500 |
New stocks bought by Fairmount Funds Management LLC
Additions
| Ticker | % Inc. |
|---|---|
| viridian therapeutics inc | 30.05 |
Additions to existing portfolio by Fairmount Funds Management LLC
Reductions
None of the existing positions were reduced by Fairmount Funds Management LLC
Sold off
| Ticker | $ Sold |
|---|---|
| spyre therapeutics inc | -202,673,000 |
Fairmount Funds Management LLC got rid off the above stocks
Sector Distribution
Fairmount Funds Management LLC has about 55.7% of it's holdings in Others sector.
- Others
- Healthcare
| Sector | % |
|---|---|
| Others | 55.7 |
| Healthcare | 44.3 |
Market Cap. Distribution
Fairmount Funds Management LLC has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.
- UNALLOCATED
- SMALL-CAP
- MID-CAP
- MICRO-CAP
- NANO-CAP
| Category | % |
|---|---|
| UNALLOCATED | 55.7 |
| SMALL-CAP | 21.7 |
| MID-CAP | 20.3 |
| MICRO-CAP | 1.2 |
| NANO-CAP | 1.2 |
Stocks belong to which Index?
About 26.9% of the stocks held by Fairmount Funds Management LLC either belong to S&P 500 or RUSSELL 2000 index.
- Others
- RUSSELL 2000
| Index | % |
|---|---|
| Others | 73.1 |
| RUSSELL 2000 | 26.9 |
| Top 5 Winners (%) | % | |
|---|---|---|
oruka therapeutics inc | 94.0 % | |
| AVTE | jade biosciences inc | 58.1 % |
apogee therapeutics inc | 57.7 % | |
zenas biopharma inc | 29.8 % | |
enliven therapeutics inc | 29.5 % | |
| Top 5 Winners ($) | $ | |
|---|---|---|
oruka therapeutics inc | 170.9 M | |
| AVTE | jade biosciences inc | 37.2 M |
dianthus therapeutics inc | 34.4 M | |
enliven therapeutics inc | 21.4 M | |
apogee therapeutics inc | 14.5 M | |
| Top 5 Losers (%) | % | |
|---|---|---|
| VRDN | viridian therapeutics inc | -5.4 % |
crescent biopharma inc. | -2.0 % | |
| Top 5 Losers ($) | $ | |
|---|---|---|
| VRDN | viridian therapeutics inc | -5.4 M |
crescent biopharma inc. | -1.0 M | |
Fairmount Funds Management LLC Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Fairmount Funds Management LLC
Fairmount Funds Management LLC has 12 stocks in it's portfolio. VRDN proved to be the most loss making stock for the portfolio. was the most profitable stock for Fairmount Funds Management LLC last quarter.
$1.51BTotal Value
13.00Positions
14 Aug, 2026Last Reported
| Expand | Holdingsorted ascending | % Portfolio | Shares Held | $ Value | % Change |
|---|---|---|---|---|---|
 Spyre Therapeutics Inc Fairmount Funds Management LLC's holding in Spyre Therapeutics Inc over time | 0% | 0.00 | $0.00 0% | 100%decreased 100 percentsold off | |
 Jade Biosciences Inc Fairmount Funds Management LLC's holding in Jade Biosciences Inc over time | 6.69% | 4,553,490 | $101.18M 6.69% | 0%unchanged 0 percentunchanged | |
 Cogent Biosciences Inc Fairmount Funds Management LLC's holding in Cogent Biosciences Inc over time | 14.08% | 5,503,420 | $212.98M 14.08% | 0%unchanged 0 percentunchanged | |
 Damora Therapeutics Inc Fairmount Funds Management LLC's holding in Damora Therapeutics Inc over time | 14.98% | 8,713,000 | $226.63M 14.98% | 0%unchanged 0 percentunchanged | |
 Inhibikase Therapeutics Inc Fairmount Funds Management LLC's holding in Inhibikase Therapeutics Inc over time | 1.16% | 8,625,000 | $17.51M 1.16% | 0%unchanged 0 percentunchanged | |
 Faeth Therapeutics Inc Fairmount Funds Management LLC's holding in Faeth Therapeutics Inc over time | 1.19% | 722,020 | $18.05M 1.19% | Newnew position | |
 Viridian Therapeutics Inc Fairmount Funds Management LLC's holding in Viridian Therapeutics Inc over time | 6.18% | 5,090,930 | $93.52M 6.18% | 30.05%increased 30.05 percentadded | |
Com Oruka Therapeutics IncOruka Therapeutics Inc | 23.31% | 3,705,260 | $352.63M 23.31% | 0%unchanged 0 percentunchanged | |
Com Dianthus Therapeutics IncDianthus Therapeutics Inc | 16.35% | 2,537,190 | $247.32M 16.35% | 0%unchanged 0 percentunchanged | |
Com Enliven Therapeutics IncEnliven Therapeutics Inc | 6.22% | 1,855,640 | $94.17M 6.22% | 0%unchanged 0 percentunchanged | |
Com Zenas Biopharma IncZenas Biopharma Inc | 3.96% | 2,359,020 | $59.87M 3.96% | 0%unchanged 0 percentunchanged | |
Com Crescent Biopharma Inc.Crescent Biopharma Inc. | 3.27% | 2,747,870 | $49.46M 3.27% | 0%unchanged 0 percentunchanged | |
Com Apogee Therapeutics IncApogee Therapeutics Inc | 2.62% | 298,647 | $39.64M 2.62% | 0%unchanged 0 percentunchanged | |